Table 2.
Phase III clinical trials currently active or completed
| Candidate | Construct | Condition | Clinical Trials Identifier |
|---|---|---|---|
| MDX‐1379 | Two peptides from gp100 melanocyte protein | Metastatic melanoma | NCT00094653 |
| PR1 leukaemia peptide vaccine | Derived from proteinase 3 and neutrophil elastase | Acute myeloid leukemia | NCT00454168 |
| Telomerase peptide vaccine GV1001 | Derived from reverse transcriptase subunit of telomerase (hTERT) | Pancreatic cancer | NCT00425360 |
| NeuVax | Derived from human leukocyte antigen HER2 | Breast cancer | NCT01479244 |
| NeuroVax | Two peptides from T‐cell receptor | Multiple sclerosis | NCT02057159 |
| MAGE‐A3 and NY‐ESO‐1 Immunotherapy | Peptides from MAGE‐A3 and NY‐ESO‐1 proteins | Multiple myeloma | NCT00090493 |
| Diapep277 | T‐cell epitope of heat shock protein 60 | Type 1 diabetes | NCT01281072 |